Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc., a leading biopharmaceutical company based in the United States, is dedicated to transforming the lives of patients with rare diseases and cancers. Founded in 2010, Forma has made significant strides in drug discovery and development, focusing on innovative therapies that target specific genetic mutations. With a strong emphasis on precision medicine, Forma Therapeutics is renowned for its unique approach to developing small molecule therapies, particularly in the areas of sickle cell disease and other haematological disorders. The company has achieved notable milestones, including advancing its lead product candidates through various stages of clinical trials, positioning itself as a key player in the biopharmaceutical industry. Through its commitment to scientific excellence and patient-centric solutions, Forma Therapeutics continues to enhance its market position, striving to deliver transformative treatments that address unmet medical needs.
DitchCarbon Score
How does Forma Therapeutics Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Forma Therapeutics Holdings, Inc.'s score of 73 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Forma Therapeutics Holdings, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Novo Nordisk A/S, and as such, it inherits emissions data and climate commitments from its parent organisation. While Forma Therapeutics has not disclosed its own emissions figures, it aligns with the sustainability initiatives and targets set by Novo Nordisk A/S. This includes commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing carbon emissions and promoting renewable energy usage. As a subsidiary, Forma Therapeutics is expected to contribute to the overarching climate goals established by Novo Nordisk, which include significant reduction targets across various scopes of emissions. However, specific reduction targets or achievements for Forma Therapeutics itself have not been detailed. In summary, while Forma Therapeutics Holdings, Inc. does not provide its own emissions data or specific climate commitments, it is part of a corporate family that prioritises sustainability and has established frameworks for reducing carbon emissions through its parent company, Novo Nordisk A/S.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Forma Therapeutics Holdings, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
